Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) EBIT Margin (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed EBIT Margin for 7 consecutive years, with 3411.01% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 231884.0% to 3411.01% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 891.1% through Dec 2025, down 33528.0% year-over-year, with the annual reading at 891.07% for FY2025, 33526.0% down from the prior year.
  • EBIT Margin for Q4 2025 was 3411.01% at Kymera Therapeutics, down from 3347.36% in the prior quarter.
  • The five-year high for EBIT Margin was 40.33% in Q4 2023, with the low at 3411.01% in Q4 2025.
  • Average EBIT Margin over 5 years is 781.29%, with a median of 369.14% recorded in 2022.
  • The sharpest move saw EBIT Margin surged 29809bps in 2021, then tumbled -231884bps in 2025.
  • Over 5 years, EBIT Margin stood at 222.55% in 2021, then dropped by -8bps to 239.36% in 2022, then skyrocketed by 83bps to 40.33% in 2023, then tumbled by -2608bps to 1092.17% in 2024, then tumbled by -212bps to 3411.01% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 3411.01%, 3347.36%, and 736.82% for Q4 2025, Q3 2025, and Q2 2025 respectively.